This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HuMax-IL15
Description: HuMax-IL15 is a fully human monoclonal antibody against interleukin-15 (IL-15). Its preclinical anti-inflammatory effects make it a candidate for development in the management of a wide array of conditions mediated by inflammation.
Amgen (Immunex) and Genmab
Immunex, which has since been acquired by Amgen, licensed rights to develop an antibody to IL-15 and its receptor to Genmab in May 1999. Amgen has the option to take over development and marketing of HuMax-IL15 after Genmab completes phase II trials, in which case Genmab and Amgen will share development costs and profits 50/50. Amgen exercised that option in July 2003, in advance of phase II data release.
Medarex and Genmab produced HuMax-IL15 using Medarex's transgenic mouse system.
Bristol-Myers Squibb and Medarex
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.
Celimmune and Amgen
In March 2015, Celimmune announced that it has licensed AMG 714 from Amgen. Under the provisions...See full deal structure in Biomedtracker
Partners: Genmab A/S Bristol-Myers Squibb Company Amgen, Inc.
AMG 714 News
Additional information available to subscribers only: